U.S. markets closed
  • S&P 500

    3,963.51
    +29.59 (+0.75%)
     
  • Dow 30

    33,781.48
    +183.56 (+0.55%)
     
  • Nasdaq

    11,082.00
    +123.45 (+1.13%)
     
  • Russell 2000

    1,818.29
    +11.39 (+0.63%)
     
  • Crude Oil

    72.05
    +0.59 (+0.83%)
     
  • Gold

    1,802.10
    +0.60 (+0.03%)
     
  • Silver

    23.32
    +0.07 (+0.30%)
     
  • EUR/USD

    1.0563
    +0.0049 (+0.46%)
     
  • 10-Yr Bond

    3.4910
    +0.0830 (+2.44%)
     
  • GBP/USD

    1.2236
    +0.0031 (+0.25%)
     
  • USD/JPY

    136.5270
    +0.0030 (+0.00%)
     
  • BTC-USD

    17,213.44
    +357.26 (+2.12%)
     
  • CMC Crypto 200

    405.01
    +10.32 (+2.62%)
     
  • FTSE 100

    7,472.17
    -17.02 (-0.23%)
     
  • Nikkei 225

    27,574.43
    -111.97 (-0.40%)
     

Aclaris Therapeutics (NASDAQ:ACRS) pulls back 7.4% this week, but still delivers shareholders massive 110% CAGR over 3 years

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) shareholders have seen the share price descend 10% over the month. But over three years the performance has been really wonderful. In fact, the share price has taken off in that time, up 821%. Arguably, the recent fall is to be expected after such a strong rise. The only way to form a view of whether the current price is justified is to consider the merits of the business itself. Anyone who held for that rewarding ride would probably be keen to talk about it.

Since the long term performance has been good but there's been a recent pullback of 7.4%, let's check if the fundamentals match the share price.

Check out our latest analysis for Aclaris Therapeutics

Given that Aclaris Therapeutics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Aclaris Therapeutics' revenue trended up 13% each year over three years. That's pretty nice growth. Arguably the very strong share price gain of 110% a year is very generous when compared to the revenue growth. A hot stock like this is usually well worth taking a closer look at, as long as you don't let the fear of missing out (FOMO) impact your thinking.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

A Different Perspective

Aclaris Therapeutics shareholders are down 15% over twelve months, which isn't far from the market return of -16%. So last year was actually even worse than the last five years, which cost shareholders 7% per year. It will probably take a substantial improvement in the fundamental performance for the company to reverse this trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 3 warning signs we've spotted with Aclaris Therapeutics (including 1 which is a bit unpleasant) .

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here